Related by context. All words. (Click for frequent words.) 65 ABSORB trial 65 confirmatory clinical 64 phase IIa clinical 64 AVN# Phase 64 Zemplar Capsules 64 Phase 1b trial 63 ENDEAVOR IV 63 Phase Ib IIa 63 EchoCRT 63 prospective multicentre 63 placebo controlled multicenter 62 Phase #/#a 62 mg/m2 cohort 62 CARE HF 62 dose escalation phase 62 budesonide MMX Phase III 62 biostatistical analysis 62 multicenter Phase II 62 Phase III multicenter 62 HDL Selective Delipidation 62 MEND CABG 62 Phase #b/#a clinical 61 ThermoDox ® clinical 61 Phase Ib study 61 MEND CABG II 61 CRLX# 61 prospectively stratified 61 number NCT# ClinicalTrials.gov 61 HORIZONS AMI trial 61 PROTECT II 61 INTEGRILIN R eptifibatide Injection 61 BioSante LibiGel Phase III 61 EMPOWER ™ 61 Phase Ib clinical 61 Phase Ib II 61 PRIMO CABG 61 YONDELIS 61 REALITY Trial 61 pharmacokinetic PK study 61 IMPACT DCM 61 PARTNER Trial 61 CRMD# 61 TEMSO 61 placebo controlled clinical 61 CALGB 61 XL# SAR# 61 PRESEPT 61 Phase IIIb clinical 61 undergoing elective percutaneous 60 EMPOWER TM 60 BRIM3 60 Phase 1b clinical trials 60 NSABP C 60 SPIRIT FIRST 60 Androxal TM 60 LUMINATE 60 Phase III ADT 60 Phase 2b RESTORE CLI 60 Trofex 60 SYMMETRY trial 60 APEX PD 60 Phase III VISTA 60 Refractory Angina 60 rALLy clinical trial 60 Urocortin 2 60 EDEMA3 trial 60 oral ridaforolimus 60 SUCCEED trial 60 ADVANCE PD 60 CURE AF 60 riociguat 60 phase IIb study 60 EVEREST II 60 clevidipine 60 Phase IIb III 60 alvespimycin 60 Circulatory Support 60 midstage clinical 60 multicenter randomized clinical 60 GENASIS trial 60 Phase 2b kidney transplant 60 NeuroFlo 60 ongoing Phase 1b 60 basal bolus regimen 60 GAMMAGARD 60 RESTORE CLI 59 IMPACT DCM clinical 59 TG MV 59 ORBIT II 59 pivotal bioequivalence 59 Empatic ™ 59 Proellex TM 59 phase IIa 59 evaluating Actimmune 59 PFO migraine 59 oral picoplatin 59 BARI 2D 59 Zenvia ™ 59 COSIRA trial 59 catheter occlusion 59 relapsed MM 59 Andara TM OFS 59 Phase IIIb study 59 prospective nonrandomized 59 phase IIb clinical 59 subcutaneous PRO 59 mITT population 59 SIMPADICO 59 novel oral anticoagulant 59 MIST II 59 PROTECT AF 59 Angiox R 59 ENDEAVOR III 59 NP2 Enkephalin 59 EDEMA3 59 Perforomist ™ Inhalation Solution 59 Aeolus Pharmaceuticals Announces 59 Randomized controlled 59 Edge STudy 59 CLARITY study 59 Phase #b/#a 59 prospective multicenter study 59 VESTASYNC II trial 59 NEUVENGE 59 Phase 1a clinical 59 STRIDE PD 59 evaluating tivozanib 59 BCIRG 59 NO# [002] 59 oral talactoferrin 59 Edwards SAPIEN valve 59 im peramivir 59 Dr. Pingpank 59 radiographic outcomes 59 OLYMPIA registry 59 Crofelemer budesonide foam 59 trastuzumab DM1 T DM1 59 SUTENT ® 59 APEX AMI 59 recombinant PSMA vaccine 59 Delcath Phase III 59 Carotid Revascularization Endarterectomy vs. 59 ATACAND 59 RSD# oral 59 ONTARGET 59 GENASIS clinical 59 ABSORB clinical 59 Duromist ™ 59 coronary stent merged 59 REVIVE Diabetes 59 multicenter clinical 59 multicenter Phase 59 PDE# inhibitors 59 EXPLORE Xa 58 Lixivaptan 58 placebo controlled Phase III 58 Neovasc Reducer 58 TransVax ™ 58 Dialysis Outcomes 58 multicenter prospective 58 PRIMO CABG2 58 HIV coinfected 58 placebo controlled dose escalation 58 blinded randomized placebo controlled 58 ASCEND HF 58 CHAMPION PCI 58 antiretroviral naïve 58 fosbretabulin 58 Phase 2a trial 58 CA9 SCAN 58 Resolute DES 58 ADAGIO study 58 INTERCEPT platelets 58 zileuton IV 58 Option IVC Filter 58 VTE prevention 58 randomized Phase IIb 58 Lung Rx 58 CINQUIL 58 Anturol TM 58 forodesine 58 HeartNet 58 Phase III LibiGel 58 Phase III metastatic melanoma 58 CALGB # [002] 58 myoblast therapy 58 Phase #/#a trial 58 LibiGel Phase III 58 Fibrin Pad 58 PRECISE Trial 58 treatment naïve genotype 58 deforolimus 58 Dr. Yatscoff 58 phase IIb trial 58 JenaValve 58 randomized controlled multicenter 58 randomized Phase 2b 58 ICAEL 58 StemEx R 58 phase IIb III 58 AVERROES 58 Vascugel 58 AFRS TM 58 recurrent glioma 58 PROMUS R 58 PreCISe 58 Jal S. Jassawalla 58 ToGA 58 EmbraceAC 58 BLA filing 58 EOquin TM 58 unstable angina UA 58 Robert Motzer MD 58 ularitide 58 teriflunomide 58 maximally tolerated dose 58 evaluating mipomersen 58 viral kinetic 58 INSPIRE Trial Phase III 58 acyclovir Lauriad R 58 phase IIIb 58 MAGE A3 ASCI 58 Bayer HealthCare Onyx Pharmaceuticals 58 budesonide foam 58 Aryplase 58 ENRICH trial 58 BRIM2 58 Budesonide foam crofelemer 58 CLIRS 58 QTinno TM 58 Therapeutics TCT scientific 58 DSMB recommended 58 Holly Graft 58 LipiScan 58 Phase III confirmatory 58 ICON7 58 INTEGRILIN 58 VITAL Trial 58 MelaFind R 58 Pharmacokinetic parameters 58 preclinical efficacy 58 ARISE Phase III 58 treatment naive genotype 58 assessing T DM1 58 multicenter randomized Phase 58 randomized discontinuation 58 somatostatin analog 58 Pre RELAX AHF 58 ® pioglitazone HCl 57 TAXUS VI 57 XIENCE V Everolimus Eluting 57 Secondary efficacy endpoints 57 Vascugel ® 57 evaluating REVLIMID 57 kidney urologic 57 multicentre prospective 57 AIR2 Trial 57 SinuNase ™ 57 Acute Decompensated Heart Failure 57 evaluating Prochymal 57 azilsartan medoxomil 57 sNDA submission 57 BrachySil TM 57 Laura Mauri 57 chronic myocardial ischemia 57 NABTT 57 trastuzumab emtansine T DM1 57 CUSTOM III 57 AIM HIGH 57 GENASIS 57 SABCS 57 RX ACCULINK 57 Marc Oczachowski 57 TransVax tm 57 Manja Bouman CEO 57 pharmacokinetic PK 57 UA NSTEMI 57 EECP R 57 ENMD # 57 Levacor 57 MERLIN TIMI 57 vidofludimus 57 SNT-MC#/idebenone 57 thorough QT 57 tramiprosate Alzhemed TM 57 LCP AtorFen 57 RESOLUTE clinical 57 generation rotary VAD 57 #th Annual Interscience 57 ZYBRESTAT fosbretabulin 57 multicenter trials 57 Rigel R# 57 LibiGel ® 57 NCCTG 57 mild hepatic impairment 57 ELACYT 57 CIMZIA TM certolizumab pegol 57 Diamondback #deg 57 Dr. Fahar Merchant 57 Rheos System 57 USpella 57 Urocidin ™ 57 ExTRACT TIMI 57 Phase 1b clinical 57 FOLFOX6 chemotherapy regimen 57 cerebral oximetry 57 TOLAMBA 57 Kathy Giusti myeloma 57 successfully commercialize Iluvien 57 HF ACTION 57 pharmacodynamic effects 57 CATIE AD 57 Mr. Fater 57 GRAVITAS trial 57 brivaracetam 57 delivers fluocinolone acetonide FA 57 CTAP# Capsules 57 TASKi3 57 Surfaxin LS 57 Trobalt 57 CaPSURE 57 Acute Coronary Syndromes ACS 57 VBLOC TM 57 retinal vein occlusion induced 57 Phase III psoriasis 57 HuMax CD#b 57 pradefovir 57 VANTAS ® 57 Phe restricted diet 57 ASCO GI 57 visceral metastases 57 APTIVUS 57 EECP ® therapy 57 rALLy trial 57 SCAI Annual 57 EASE Trial 57 ALTROPANE 57 pharmacogenomic translational research 57 cerebral somatic oximeter 57 phase IIb 57 IMPROVE HF 57 nonrandomized 57 sapacitabine CYC# 57 LibiGel ® testosterone gel 57 GEM OS2 57 skin sterol 57 BioNumerik 57 de novo kidney transplant 57 phase Ib 57 Ophena 57 Mark A. Sirgo 57 UVIDEM 57 HQK 57 recurrent glioblastoma multiforme 57 Angiox ® 57 multicenter randomized controlled 57 Phase lll 57 carotid artery stenting 57 Dose escalation 57 Oral NKTR 57 Phase Ib Clinical Trial 57 REVEAL Registry 57 urethral bulking agent 57 APEX AMI trial 57 florbetaben 57 Val HeFT 57 personalized cellular immunotherapy 57 Aflibercept 57 Pyridorin 57 morphometric vertebral fractures 56 myocardial revascularization 56 RenalGuard System TM 56 ACRIN 56 TM Embolic Protection 56 dose escalation clinical 56 volociximab 56 Coherex FlatStent 56 NV1FGF 56 pelvic malignancies 56 glycoprotein IIb IIIa inhibitor 56 MelaFind pivotal 56 HCD# [002] 56 ImmuKnow assay 56 ACUITY trial 56 Harry Palmin President 56 double blinded randomized 56 DEB# 56 #rd Annual CTRC 56 designated HVTN 56 reduce serum phosphate 56 OvaRex ® MAb 56 Augment Injectable 56 SYNTAX trial 56 fully bioabsorbable 56 prospective observational 56 OmniWave 56 Jean Claude Tardif 56 ALSYMPCA 56 galiximab 56 oral rivaroxaban 56 mertansine 56 GOUT 56 QOPI 56 PCI ExTRACT TIMI 56 APPRAISE 56 PLCO 56 RE LY ® 56 PORxin TM platforms 56 Acute MI 56 Spectranetics laser 56 multicentre randomized controlled 56 confirmatory Phase III 56 Diabetic Macular Edema DME 56 Capesaris 56 deCODE AF TM 56 prospective observational studies 56 Zolpimist ™ 56 trodusquemine 56 initiate multicenter 56 StemEx 56 prelicensure 56 NCT# ClinicalTrials.gov 56 Cotavance 56 samalizumab 56 PANVAC VF 56 INS# [002] 56 Plicera 56 ADMIRE HF 56 ACTEMRA TM 56 solid tumors ZYBRESTAT 56 PrevOnco ™ 56 ALN VSP Phase 56 Steven R. Deitcher 56 DEEP AF 56 Gregory D. Casciaro 56 DDP# 56 AA Amyloidosis 56 OvaRex R 56 Professor Eberhard Grube 56 IONSYS TM 56 BrachySil ™ 56 PSMA ADC 56 XIENCE V Stent System 56 SEPET TM 56 Orqis Medical 56 prospective observational cohort 56 ragweed allergic children 56 R sorafenib tablets 56 CLIRS trial 56 thrombin inhibiting aptamer 56 ZOLINZA 56 TAXUS Liberté stent 56 blinded randomized controlled 56 REMINYL ® 56 Gentamicin Surgical Implant 56 Eckard Weber 56 BioMatrix TM 56 octreotide implant 56 Endoscopic Ablation System 56 Viprinex TM 56 Allovectin 7 ® 56 Confirmatory tests 56 MGN# 56 acetonide FA 56 GetGoal Phase III 56 recurrent malignant glioma 56 metaglidasen 56 microbiologically evaluable 56 eTag assays 56 atherosclerotic renal artery stenosis 56 Dr. Laikind 56 AngioJet thrombectomy 56 lumiliximab 56 ASSERT trial 56 BioZ ICG 56 lomitapide 56 Microwave Ablation System 56 Exelixis compounds 56 Platinum Chromium Coronary Stent 56 Randomized clinical trials 56 compound INCB# 56 CryoPlasty 56 epoetin alpha 56 PROMUS TM 56 EndoBarrier ™ 56 OMAPRO ™ 56 Elisabeth Lindner CEO 56 bavituximab monotherapy trial 56 Targretin capsules 56 ATIR ™ 56 Dacogen injection 56 Virulizin ® 56 everolimus eluting stents 56 NATRECOR ® 56 Canvaxin 56 Phase #b/#a trial 56 Canvaxin TM 56 MGuard ™ 56 inhaled AAT 56 AIR CF1 56 carotid endarterectomy CEA 56 QTinno 56 TAXUS TM 56 noninvasive outpatient 56 AERx iDMS 56 CRRT 56 IMPACT DCM trial 56 PDX pralatrexate 56 Prosaptide 56 refractory angina 56 SoftScan R 56 PROPEL trial 56 ACTIVE W 56 vaginally administered lidocaine 56 ASCO Breast Cancer 56 sirolimus eluting stents 56 Raptiva r 56 R#/MEM # 56 NATRECOR R 56 Patrick Serruys 56 Echocardiographic 56 Dr. Assa Amit 56 mSEPT9 biomarker 56 Georges Gemayel 56 PresbyLens ® 56 Robert L. Chioini 56 Calmare pain 56 BACcel 56 Phase IIB 56 zileuton injection 56 RE MODEL 56 Kiadis Pharma 55 ADVEXIN therapy 55 RAPAFLO R 55 CTO recanalization 55 orally inhaled migraine 55 HORIZONS AMI 55 Spheramine 55 OncoGel 55 maximally tolerated lipid lowering 55 Generx TM 55 transgenically produced product 55 dipyridamole plus 55 efficacy endpoint 55 Phase III Psoriasis 55 onset AF 55 NCIC CTG 55 Phase IIb clinical trials 55 Cardio3KG 55 ENGAGE AF TIMI 55 ACC NCDR 55 Hedgehog Pathway Inhibitor 55 Cascade LifeSciences 55 MoxDuo IR 55 By JENNIFER LEARN 55 Screening Trial DMIST 55 EP #R 55 OZURDEX 55 Bioaccelerate compounds under 55 PROactive study 55 EGS# 55 prospective randomized multicenter 55 PLX STROKE targeting 55 Hepatocellular Carcinoma HCC 55 malignant mesothelioma Alfacell 55 IMA# 55 retrospective observational 55 pain palliation 55 valopicitabine NM# 55 incyclinide 55 MVA MUC1 IL2 55 PrevOnco 55 velafermin 55 antiarrhythmic drug 55 John JP Kastelein 55 ReN# 55 ZFP Therapeutics 55 HuMax EGFr 55 cathepsin K inhibitor 55 percutaneous cryoablation 55 Angiotensin Therapeutic Vaccine 55 ENDEAVOR clinical 55 Cardiovascular Anesthesiologists 55 clinical pharmacology studies 55 recurrent metastatic ovarian cancer 55 randomized controlled Phase 55 SoftScan ® 55 recurrent metastatic 55 HepeX B TM 55 Cand5 55 COR Analyzer 55 Metricath 55 R vitespen 55 PF # [002] 55 Simulect 55 oral methylnaltrexone 55 Panzem ® 55 O PPDS 55 eritoran 55 Embolic Protection Device 55 Altastaph 55 MYDICAR 55 Ablatherm R 55 VBLOC vagal blocking 55 Diamyd R 55 Octreolin 55 website http:/www.celsion.com 55 MitraClip device 55 dyslipidemia hypertension diabetes 55 Karl Heinz Kuck 55 Medidur FA 55 Phase IIIb 55 refractory colorectal cancer 55 NAVISTAR R 55 Adaptive Radiation Therapy 55 prospective multicenter randomized 55 CAMMS# 55 MGd 55 SNT MC# 55 adjuvant GIST 55 AZILECT ® 55 OMNARIS HFA 55 Dextofisopam 55 PEGylated interferon 55 CCX# B 55 OMS# 55 AVADO 55 eprotirome 55 ACCORD Lipid 55 Primary endpoints 55 PROactive Study 55 dose escalation Phase 55 varespladib 55 elotuzumab 55 Carl Spana Ph.D. 55 GVAX ® 55 multicenter clinical trials 55 lucinactant 55 Endeavor drug eluting 55 VESTASYNC 55 OHR/AVR# 55 Phase IIIB IV 55 motesanib diphosphate 55 3 registrational trial 55 Solorel TM 55 Bystolic nebivolol 55 bioequivalency 55 Allovectin 7 55 Hedgehog antagonist 55 prospective multicenter 55 lorvotuzumab mertansine 55 ponatinib 55 TRIST study 55 develop HBV reactivation 55 initiate Phase 1b 55 rheumatoid arthritis osteoarthritis ankylosing 55 multicentre study 55 TBC# 55 Digestive Diseases Week 55 HuCAL antibodies 55 JAK#/JAK# inhibitor CYT# 55 XIENCE 55 Nanobody R 55 patientswith 55 opioid induced bowel dysfunction 55 PROCHYMAL 55 unstable angina pectoris 55 Braunwald 55 tolevamer 55 Endeavor DES 55 DDW ® 55 LEVADEX ™ 55 Myoblast Program 55 multicenter phase 55 Medidur TM FA 55 ILLUMINATE 55 Solazed 55 Oracea TM 55 Bezielle 55 PRECISE trial 55 CIMZIA ™ 55 Septin9 biomarker 55 Connective Tissue Oncology 55 cariprazine 55 e2 Collector 55 multicenter Phase III 55 Certolizumab pegol 55 THALOMID 55 Arzerra TM 55 BoNTA 55 Tectin TM 55 C7 XR 55 Initiates Enrollment 55 AACR San Antonio 55 Acute Ischemic Stroke 55 Transcatheter aortic valve implantation 55 Marie Claude Morice 55 TAXUS V 55 RE LY 55 SNS# T 55 ARVO 55 Renal Cell Carcinoma RCC 55 Arno Therapeutics 55 ARCOXIA 55 IMiDs ® compound 55 HepaMate 55 Demonstrates Sustained 55 randomizing patients 55 endothelin antagonists 55 Phase IIb REGENESIS 55 Deforolimus 55 hyperphenylalaninemia HPA due 55 Tarvacin Anti Cancer 55 oral deforolimus 54 ZoMaxx 54 adenosine injection 54 SYN# 54 undergoing coronary angiography 54 iii GTx 54 OvaRex MAb 54 bioabsorbable drug eluting 54 human IgG1 monoclonal 54 André Michel Ballester 54 Teriflunomide 54 lintuzumab SGN 54 multicentre randomized 54 either acutely decompensated 54 Alexandre Abizaid 54 IIa trial 54 Silodosin 54 VEITHsymposium 54 confirmatory pivotal 54 Immunotherapeutic 54 neratinib 54 Phase 2b study 54 PI3K/Akt pathway inhibitor 54 PHX# 54 QLT# 54 pharmacokinetic pharmacodynamic 54 ExCell study 54 Phase #/#a clinical 54 relapsed MCL 54 PROMACTA CARES 54 pyrimidine nucleoside analog 54 MADIT II 54 UPLYSO 54 CMV vaccine 54 NEVO TM 54 TRO# 54 MAA submission 54 RhuDex 54 Tovaxin TM 54 glucocorticoid induced osteoporosis 54 Numoda 54 nalbuphine ER 54 ORMD 54 prednisone prednisolone plus 54 administered intramuscularly 54 Dr. Fehlings 54 PEG SN# 54 pharmacologic stress 54 Entereg R 54 ROCKET AF 54 DMD DMSc 54 novel therapeutic antibodies 54 Phase III randomized controlled 54 formal pharmacokinetic PK 54 plasma pharmacokinetics 54 null responder HCV 54 ACAPODENE TM 54 CVx ChannelVision Expo 54 TTF Therapy 54 ENABLE Phase 2 54 intradermal injections 54 TAXUS ATLAS 54 BiTE R 54 Nasdaq PGNX today 54 Telatinib 54 AACR #st Annual Meeting 54 Novolimus 54 dose proportionality 54 Lauren Silvernail 54 Digital Mammographic Imaging 54 Phase III HEAT 54 FACTIVE tablets 54 BRILINTA 54 including eniluracil ADH 54 Xelox 54 Levulan ® PDT 54 Non inferiority 54 steroid refractory 54 ICAAC IDSA 54 PRESEPT Study 54 Joseph K. Belanoff 54 journal Gynecologic Oncology 54 periodically reassessed 54 cerebral oximeter 54 HuMax CD4 54 metastatic pancreatic 54 oral PTH 54 regorafenib 54 dual antiplatelet 54 genomic biomarker 54 deCODE ProstateCancer TM 54 ® natalizumab 54 methodologically rigorous 54 severe hypercholesterolemia 54 ThermoDox R 54 sacral nerve stimulation 54 Dr. Tashkin 54 PERSEUS 54 refractory CLL 54 MediServe 54 EVIZON TM 54 pharmacodynamic properties 54 Current Controlled Trials 54 ENTOCORT EC 54 Phase Ib IIa clinical 54 WILEX 54 candidate TNFerade biologic 54 MADIT 54 preclinically 54 ER CHOP 54 poststroke depression 54 HBV infections 54 Chemophase 54 neoadjuvant treatment 54 NLX P# 54 commercialize CorMedix drug 54 Dr. Agarwala 54 ACCLAIM II 54 NeuroStar TMS Therapy 54 Resurgex Plus 54 demonstrated clinically meaningful 54 evaluating T DM1 54 Triapine R 54 headache nasopharyngitis 54 EnteroMedics proprietary neuroblocking technology 54 torezolid phosphate 54 tecarfarin 54 commercialize ZYFLO CR 54 Aalst Belgium 54 Volumex Daxor single 54 Potiga 54 selective androgen receptor modulator 54 CERVARIX 54 HGS# 54 lorcaserin Phase 54 Nasulin ™ 54 Ascendra 54 CardioFit 54 iliac artery disease 54 Kahalalide F 54 AFREZZA TM 54 Q#IR 54 Amoxicillin PULSYS Phase III 54 Genitourinary Cancer 54 Amorcyte 54 JAK inhibitor 54 tolerability profiles 54 dual endothelin receptor antagonist 54 Quinamed 54 next generation URAT1 54 Phase 2b randomized 54 HeartMate ® 54 RCW breast cancer 54 Group RTOG 54 pharmacokinetic characteristics 54 Zevalin consolidation 54 NOXAFIL Oral Suspension 54 IL# PE#QQR 54 Aloxi injection 54 Vascular Wrap TM 54 randomized Phase III 54 Late Breaker 54 Fibrillex TM 54 cediranib 54 Everolimus Eluting Coronary Stent 54 allogeneic HSCT 54 microplasmin Phase III 54 GCP compliant 54 ORAL Sync 54 CLENZIderm MD 54 carotid artery stenting CAS 54 Custom NX R 54 CYT# potent vascular disrupting 54 Certican 54 Neuradiab 54 Dural Sealant 54 CR# vcMMAE 54 NSABP 54 ganetespib 54 SMT C# 54 TASKi2 54 via intradermal injections 54 ALN HTT 54 blind multicenter 54 FOLOTYN ® 54 AZOR 54 blinded randomized 54 Forodesine HCl 54 multicenter multinational 54 IntuiTrak 54 ongoing Phase IIIb 54 Bellicum 54 unique alkylating agent 54 Dr. Ayalew Tefferi 54 Angiographic 54 elective PCI 54 coronary revascularisation 54 Vaxfectin TM 54 HYVET 54 opioid naive 54 RE LY trial 54 PROMUS Element Stent 54 Bicifadine 54 myelodysplastic myeloproliferative diseases 54 AUA Annual Meeting 54 relapsing remitting MS RRMS 54 topical NSAIDs 54 USL# 54 initiate Phase IIa 54 Diamyd r vaccine 54 Vascular Wrap 54 Tracleer R 54 OZURDEX ® 54 asymptomatic hyperuricemia 54 axitinib 54 Daniel Junius 54 venlafaxine XR 54 CINTREDEKIN BESUDOTOX 54 enzastaurin 54 thetreatment 54 sirolimus eluting 54 XenoPort dependence 54 TransVax 54 PDE4 inhibitor 54 Dr. Li Poa 54 postsurgical pain 54 Direct Visualization 54 novel trazodone formulation 54 PrandiMet 54 TACI Ig 54 CombAT study 54 Paul Laikind 54 Thorough QT 54 fund BioSante LibiGel 54 aplindore 54 motesanib 54 Endovascular Valve Edge 54 echocardiographic parameters 54 TM Everolimus Eluting 54 HYLENEX recombinant 54 efficacy tolerability 54 tropism testing 54 CTRC AACR San Antonio 54 Carl A. Pelzel 54 Biologics Delivery 54 prospective randomized controlled 54 Hedgehog inhibitor 54 LungAlert TM 54 initiated Phase Ib 54 AgaNase 54 Liposomal Grb 2 54 ECASS 54 Curaxin CBLC# 54 Fracture Intervention Trial 54 Phase III ThermoDox 54 ZACTIMA 54 plasma kallikrein inhibitor 54 Vaxfectin R adjuvant 54 GRN# 54 canagliflozin 54 treat dysmenorrhea 54 stent DES 54 safety tolerability pharmacokinetic 54 registrational 54 torsemide ER 54 EORTC NCI 54 Yves Rosconi President 53 AGGRASTAT ® tirofiban hydrochloride 53 BR.# 53 PLCO trial 53 IMPDH inhibitor 53 ARIXTRA 53 RX ACCULINK Carotid Stent 53 REG1 53 RecoveryRx TM 53 Urocidin TM 53 tremelimumab 53 ECTRIMS 53 fusion enhancers 53 analgesic efficacy 53 INTERCEPT treated 53 Society CTOS 53 America HFSA 53 sunitinib malate 53 TOCOSOL Camptothecin 53 Pharmacokinetic studies